Nebula Nerd Biotech Startup Archon Raises $20 Million to Revolutionize Drug Development with Innovative “Antibody Cages”
Archon, a pioneering biotech startup, has recently come out of stealth mode, announcing a substantial $20 million in seed funding. This funding is set to advance their groundbreaking work in drug development through the use of “antibody cages” or AbCs. These AbCs are ingeniously designed to enhance the efficacy of antibodies by providing a structural scaffold. This scaffold significantly boosts the likelihood of the antibodies successfully binding to their target proteins.
The cutting-edge approach adopted by Archon integrates artificial intelligence and advanced protein design technologies developed by Baker Lab at the University of Washington. By doing so, Archon is poised to set new benchmarks in the field of biologic drug development, potentially leading to more effective treatments for a variety of diseases.
